Endometrial Cancer - Mpap Test
MPapⓇ Test
Innovative
&
Precise
Convenient
&
Safety
IVD
Certificated
One Swipe to Protect Women's Health
MPapⓇ Test
Using precise methylation genetic testing technology combined with routine cervical sampling, this test helps doctors evaluate women over 40 with abnormal uterine bleeding to determine if they are at high risk for endometrial cancer. The results were published in internationally renowned journals and have received certification from the Taiwan Medical Device Authority.
Endometrial Cancer Incidence Surges, Surpassing Cervical Cancer
1st
Gynecological Cancer
5th
Female Cancers
17 per
100,000
Understanding Endometrial Cancer
Endometrial cancer refers to cancer originating from the lining of the uterus (endometrium). It occurs due to abnormal cell growth, with the potential to invade or spread to other parts of the body.
- Endometrial cancer is classified into 4 stages. Early-stage detection (Stage I/II) has a cure rate of about 80%, while late-stage detection (Stage III/IV) reduces the cure rate to 30%.
- The most common initial symptom is abnormal uterine bleeding, which may be accompanied by symptoms like painful urination or pelvic pain.
For patients with abnormal uterine bleeding, diagnosis of endometrial cancer primarily relies on highly invasive surgeries, which also carry risks such as infection, anesthesia complications, and uterine perforation.
High-Risk Groups
- Abnormal bleeding: Changes in bleeding volume, non-menstrual bleeding
- Women over 40
- Obesity (BMI>24 kg/m2)
- Cancer or diabetic patients
- Early menarche or late menopause
- Women who have never given birth
- Polycystic Ovary Syndrome
- Use of hormone medications
Prevention
- Women should prioritize their health and seek professional gynecological consultation if abnormal bleeding occurs, regardless of age.
- Control weight and develop a good exercise routine.
- Discuss the necessity of hormone supplements with a doctor.
MPapⓇ Test
- 98%Negative Predictive Value | 90% Sensitivity | Reduced Unnecessary Invasive Surgery
- Based on the "Methylation-Specific qPCR (MS-qPCR)" technology, combined with routine cervical sampling, the test detects methylation features of specific genes in DNA samples derived from abnormal bleeding.
- The test results assist doctors in evaluating whether women over 40 with abnormal uterine bleeding are at high risk for endometrial cancer, guiding decisions on whether to proceed with invasive endometrial sampling.
- Negative Predictive Value: The percentage of negative results where patients are truly not suffering from endometrial cancer.
- Sensitivity: The percentage of endometrial cancer cases accurately identified as high-risk.
Product Features
Innovation
Precise Molecular Testing
Methylation Gene Testing
98% of Low-Risk Results Are Non-Cancerous
Breakthrough
Low Invasive Sampling
Routine Cervical Sampling
Reduces 70% of Invasive Surgeries
Safety
Protect Health with One Swipe
Performed in Clinic
No Need for Anesthesia or Surgery
Technology
Clinically Verified
Multiple Studies Published in Renowned International Journals
Taiwan National Drug and Technology
Research Award
Quality
The Only Certified Diagnostic Aid
Approved by Taiwan's Food and Drug Administration
In Vitro Diagnostic (IVD) Reagent Approval
ISO15189 Certified Medical Laboratories in Taiwan
LDTs Certified
Testing Procedure
Professional Consultation
- Consult with a doctor
- Explain the test procedure
- Patient signs consent form
Sample Collection
- Verify sampling procedure
- Perform cervical cell sampling
- Sample transportation
Laboratory Analysis
- Sample processing
- DNA extraction
- Methylation result analysis
Report Explanation
- Report completed (10 working days)
- Report explanation and health consultation
- Doctor's professional evaluation and advice
※The test results are provided solely for clinical diagnostic reference by the physician.
If you have any questions about our products, please feel free to contact us!
Get in touch with us via email at service@phalanxbiotech.com or by phone at +886-3-578-1168 or +886-800-777988.